Patent Assignment
Reel/Frame 026994/0186
Patent Security Agreement (First Lien)
Recorded: 2011-09-29
Pages: 51
Assignors
ALKERMES, INC.
Executed: 2011-09-16
ALKERMES PHARMA IRELAND LIMITED
Executed: 2011-09-16
ALKERMES CONTROLLED THERAPEUTICS INC.
Executed: 2011-09-16
Assignee
MORGAN STANLEY SENIOR FUNDING, INC.
1585 BROADWAY, NEW YORK, NEW YORK, 10036
Covered Properties
(413)
Preparation of Injectable Suspensions Having Improved Injectability
Application:
12/856,198 →
Publication:
US US20100303900A1
Residual Solvent Extraction Method and Microparticles Produced Thereby
Coacervation Process
Application:
12/051,395 →
Publication:
US US20080233199A1
Quench liquids and washing systems for production of microparticles
Application:
12/140,542 →
Publication:
US US20080317865A1
Microencapsulation and Sustained Release of Biologically Active Polypeptides
Polymer-Based Sustained Release Device
Poly(Lactide-Co-Glycolide) Based Sustained Release Microcapsules Comprising a Polypeptide and a Sugar
Polymer-Based Sustained Release Device
Application:
12/483,871 →
Publication:
US US20090247463A1
Polymer-Based Sustained Release Device
Polymer-Based Sustained Release Device
Polymorphic Forms of Naltrexone
Methods for Administering Active Agents to CYP3A4 Sensitive Patients
Application:
12/241,404 →
Publication:
US US20090022823A1
Methods for Administering Aripiprazole
Naltrexone Long Acting Formulations and Methods of Use
Application:
13/037,713 →
Publication:
US US20110212985A1
Selective Opioid Compounds
Morphinan Derivatives with High Oral Bioavailability
Application:
12/727,784 →
Publication:
US US20100240691A1
Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders
Asenapine Prodrugs
Application:
12/978,298 →
Publication:
US US20110166194A1
Quaternary Ammonium Salt Prodrugs
Prodrugs of Nh-Acidic Compounds
Prodrugs of Heteraromatic Compounds
Prodrugs for the Treatment of Schizophrenia and Bipolar Disease
Application:
12/978,274 →
Publication:
US US20110166156A1
Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders
Application:
12/978,240 →
Publication:
US US20110166128A1
Morphinan Derivatives for the Treatment of Drug Overdose
Process for Synthesizing Oxidized Lactam Compounds
Process for the Synthesis of Substituted Morphinans
Application:
13/096,679 →
Publication:
US US20120010412A1
Prodrugs of Nh-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives
Methods for Treating Antipsychotic-Induced Weight Gain
Multi-Api Loading Prodrugs
Application:
61/427,026 →
Peripherally Acting Micro Opioid Antagonists
Application:
61/442,629 →
Process for the Synthesis of Quaternary Amine Compounds
Application:
61/472,016 →
Peripherally Acting Opioid Compounds
Application:
61/502,721 →
Formulations Having Improved Site Reactions
Application:
61/454,008 →
Method of modifying the release profile of sustained release compositions
Application:
11/826,694 →
Publication:
US US20080057131A1
Formulations for therapeutic agents absorbed through mucous membranes
Application:
10/175,851 →
Publication:
US US20030054045A1
Methods of Treating a Respiratory Illness by Delivering Liquid Droplet Aerosols of Crystalline Nanoparticulate Beclomethasone Having Surface Modifiers Adsorbed to the Surface of the Nanoparticulate Beclomethasone
Application:
09/577,489 →
Methods of Administering Liquid Droplet Aerosols of Nanoparticulate Drugs
Propellant-Based Nanoparticulate Dry Powder Aerosols and Method of Making
Controlled-Release Nanoparticulate Compositions
Controlled release nanoparticulate clozapine compositions
Application:
11/979,231 →
Publication:
US US20080124393A1
Nanoparticulate Anticonvulsant and Immunosuppressive Compositions
Application:
12/483,188 →
Publication:
US US20090297619A1
Controlled Release Nanoparticulate Clozapine Compositions
Application:
13/102,795 →
Publication:
US US20110300210A1
Rapidly disintegrating solid oral dosage form
Application:
10/667,470 →
Publication:
US US20040057993A1
Rapidly disintegrating solid oral dosage form
Application:
12/068,706 →
Publication:
US US20080213371A1
Nanoparticulate insulin
Application:
10/246,751 →
Publication:
US US20030095928A1
Stabilization of chemical compounds using nanoparticulate formulations
Application:
09/952,032 →
Publication:
US US20030054042A1
Stabilization of chemical compounds using nanoparticulate formulations
Application:
11/802,158 →
Publication:
US US20070224279A1
Stabilization of chemical compounds using nanoparticulate formulations
Application:
11/979,251 →
Nanoparticulate Compositions of Immunosuppressive Agents
Application:
12/121,443 →
Publication:
US US20090175951A1
Nanoparticulate Compositions Having Lysozyme as a Surface Stabilizer
Nanoparticulate Compositions of Mitogen-Activated Protein (Map) Kinase Inhibitors
Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
Application:
10/035,324 →
Publication:
US US20030129242A1
Nanoparticulate Compositions of Angiogenesis Inhibitors
Application:
11/928,250 →
Publication:
US US20080050461A1
Nanoparticulate Compositions of Angiogenesis Inhibitors
Application:
11/928,278 →
Publication:
US US20080107741A1
Nanoparticulate Compositions of Angiogenesis Inhibitors
Application:
11/928,289 →
Publication:
US US20080226732A1
Nanoparticulate compositions of angiogenesis inhibitors
Application:
12/076,247 →
Publication:
US US20080220075A1
Nanoparticulate Compositions of Angiogenesis Inhibitors
Application:
12/117,982 →
Publication:
US US20080279949A1
Nanoparticulate Compositions of Angiogenesis Inhibitors
Application:
12/870,722 →
Publication:
US US20100322852A1
Nanoparticulate Compositions of Angiogenesis Inhibitors
Application:
12/870,745 →
Publication:
US US20100322853A1
Nanoparticulate Compositions of Angiogenesis Inhibitors
Application:
12/870,749 →
Publication:
US US20100329976A1
Nanoparticulate Megestrol Formulations
Nanoparticulate megestrol formulations
Application:
11/093,149 →
Publication:
US US20050233001A1
Nanoparticulate megestrol formulations
Application:
11/472,556 →
Publication:
US US20100226989A1
Nanoparticulate Megestrol Formulations
Application:
12/826,557 →
Publication:
US US20100266705A1
Nanoparticulate fibrate formulations
Application:
11/710,607 →
Publication:
US US20070264348A1
Nanoparticulate Fibrate Formulations
Nanoparticulate Fibrate Formulations
Nanoparticulate fibrate formulations
Application:
11/979,230 →
Publication:
US US20080138424A1
Fenofibrate Dosage Forms
Application:
12/058,497 →
Publication:
US US20080241070A1
Nanoparticulate statin formulations and novel statin combinations
Application:
11/367,716 →
Publication:
US US20110027371A1
Nanoparticulate Polycosanol Formulations & Novel Polycosanol Combinations
Application:
12/704,426 →
Publication:
US US20100143962A1
Nanoparticulate meloxicam formulations
Nanoparticulate Meloxicam Formulations
Application:
12/788,203 →
Publication:
US US20100297252A1
Solid dosage forms comprising pullulan
Application:
10/705,227 →
Publication:
US US20040156895A1
Liquid dosage compositions of stable nanoparticulate active agents
Application:
10/619,539 →
Publication:
US US20040258757A1
Liquid Dosage Compositions of Stable Nanoparticulate Active Agents
Application:
13/044,450 →
Publication:
US US20110165251A1
Gamma irradiation of solid nanoparticulate active agents
Application:
10/654,600 →
Publication:
US US20040105778A1
In Vitro Methods for Evaluating the in Vivo Effectiveness of Dosage Forms of Microparticulate or Nanoparticulate Active Agent Compositions
Low viscosity liquid dosage forms
Application:
10/420,927 →
Publication:
US US20040105889A1
Low viscosity liquid dosage forms
Application:
11/979,253 →
Publication:
US US20080152585A1
Novel compositions of sildenafil free base
Application:
10/895,405 →
Publication:
US US20050042177A1
Novel nimesulide compositions
Application:
10/697,703 →
Publication:
US US20040156872A1
Novel Nimesulide Compositions
Application:
13/193,545 →
Publication:
US US20120063996A1
Nanoparticulate beclomethasone dipropionate compositions
Application:
12/292,092 →
Publication:
US US20090074873A1
Novel triamcinolone compositions
Application:
10/697,716 →
Publication:
US US20040141925A1
Novel Glipizide Compositions
Novel nifedipine compositions
Application:
10/712,259 →
Publication:
US US20040115134A1
Novel nifedipine compositions
Application:
11/980,720 →
Publication:
US US20090047209A1
Novel nifedipine compositions
Application:
12/292,395 →
Publication:
US US20090104273A1
Novel benzoyl peroxide compositions
Application:
10/677,857 →
Publication:
US US20040101566A1
Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery
Application:
10/979,792 →
Publication:
US US20050147664A1
Injectable Nanoparticulate Olanzapine Formulations
Application:
12/333,233 →
Publication:
US US20090155331A1
Injectable Nanoparticulate Olanzapine Formulations
Application:
13/024,315 →
Publication:
US US20110195095A1
Nanoparticulate benzothiophene formulations
Application:
12/232,895 →
Publication:
US US20090035366A1
Novel mometasone compositions and methods of making and using the same
Application:
11/633,088 →
Publication:
US US20120121653A1
Nanoparticulate Bisphosphonate Compositions
Injectable compositions of nanoparticulate immunosuppressive compounds
Application:
11/376,554 →
Publication:
US US20060210638A1
Nanoparticulate Corticosteroid and Antihistamine Formulations Methods of Making, and Methods of Administering Thereof
Nanoparticulate Quinazoline Derivative Formulations
Nanoparticulate lipase inhibitor formulations
Application:
11/402,257 →
Publication:
US US20060246141A1
Nanoparticulate stabilized anti-hypertensive compositions
Application:
11/437,833 →
Publication:
US US20100028439A1
Gamma Radiation Sterilized Nanoparticulate Docetaxel Compositions and Methods of Making Same
Application:
12/052,436 →
Publication:
US US20080220074A1
Nanoparticulate Carverdilol Formulations
Sterilized Nanoparticulate Glucocorticosteroid Formulations
Application:
11/275,775 →
Publication:
US US20070178051A1
Nanoparticulate tacrolimus formulations
Application:
12/071,849 →
Publication:
US US20080152720A1
Nanoparticulate Tacrolimus Formulations
Application:
12/484,073 →
Publication:
US US20090252806A1
Nanoparticulate Bicalutamide Formulations
Application:
13/039,249 →
Publication:
US US20110159054A1
Nanoparticulate formulations of docetaxel and analogues thereof
Application:
11/361,055 →
Publication:
US US20060188566A1
Aerosol and injectable formulations of nanoparticulate benzodiazepine
Application:
11/354,249 →
Publication:
US US20060198896A1
Aerosol and Injectable Formulations of Nanoparticulate Benzodiazepine
Application:
12/544,197 →
Publication:
US US20090304801A1
Nanoparticulate candesartan formulations
Application:
11/325,626 →
Publication:
US US20060165806A1
Formulations of a Nanoparticulate Finasteride, Dutasteride or Tamsulosin Hydrochloride, and Mixtures Thereof
Application:
11/372,227 →
Publication:
US US20060204588A1
Nanoparticulate benidipine compositions
Application:
11/446,589 →
Publication:
US US20070042049A1
Nanoparticulate acetaminophen formulations
Application:
11/446,564 →
Publication:
US US20060292214A1
Nanoparticulate imatinib mesylate formulations
Application:
11/446,565 →
Publication:
US US20060275372A1
Nanoparticulate ebastine formulations
Application:
11/448,984 →
Publication:
US US20070059371A1
Nanoparticulate posaconazole formulations
Application:
11/802,427 →
Publication:
US US20070281011A1
Nanoparticulate clarithromycin formulations
Application:
11/481,257 →
Publication:
US US20070015719A1
Nanoparticulate tadalafil formulations
Application:
11/520,059 →
Publication:
US US20070104792A1
Nanoparticulate aripiprazole formulations
Application:
11/520,058 →
Publication:
US US20070148100A1
Nanoparticulate Sorafenib Formulations
Application:
11/775,002 →
Publication:
US US20080213374A1
Nanoparticle dispersion containing lactam compound
Application:
11/129,807 →
Publication:
US US20090004277A1
Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
Application:
12/331,052 →
Publication:
US US20090238867A1
Combination of a Triptan and an Nsaid
Application:
12/329,566 →
Publication:
US US20090311335A1
Nanoparticulate Cinacalcet Compositions
Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochrloride
Application:
11/262,672 →
Publication:
US US20070098796A1
Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
Application:
11/373,629 →
Publication:
US US20070098791A1
Controlled Release Compositions Comprising an Antipsychotic Agent
Application:
11/569,483 →
Publication:
US US20080268043A1
Controlled release compositions comprising an acylanilide
Application:
11/329,893 →
Publication:
US US20060269596A1
Controlled Release Compositions Comprising Levetiracetam
Application:
11/568,841 →
Publication:
US US20070298098A1
Controlled Release Compositions Comprising a Cephalosporin for the Treatment of a Bacterial Infection
Application:
11/571,379 →
Publication:
US US20080069870A1
Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
Application:
11/558,202 →
Publication:
US US20070122481A1
Modified Release Loxoprofen Compositions
Application:
11/568,925 →
Publication:
US US20090297602A1
Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
Application:
11/422,226 →
Publication:
US US20080118556A1
Multiparticulate modified release composition
Application:
11/372,857 →
Publication:
US US20060240105A1
Sustained Release Aminopyridine Composition
Application:
12/626,001 →
Publication:
US US20100272807A1
Sustained Release Aminopyridine Composition
Application:
12/626,085 →
Publication:
US US20100272796A1
Sustained Release Aminopyridine Composition
Application:
12/626,036 →
Publication:
US US20100272795A1
Modified Release Famciclovir Compositions
Application:
11/568,891 →
Publication:
US US20100136106A1
Modified Release Ticlopidine Compositions
Application:
11/569,481 →
Publication:
US US20090297597A1
Alcohol Resistant Enteric Pharmaceutical Compositions
Application:
13/044,225 →
Publication:
US US20110223244A1
Compositions for Site-Specific Delivery of Imatinib and Methods of Use
Application:
12/407,684 →
Publication:
US US20120003319A9
Topiramate pharmaceutical composition
Application:
11/297,737 →
Publication:
US US20060121112A1
Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
Application:
11/571,377 →
Publication:
US US20080254114A1
Nanoparticulate and Controlled Release Compositions Comprising Prostaglandin Derivatives
Application:
11/568,698 →
Publication:
US US20090252807A1
Nanoparticulate and Controlled Release Compositions Comprising Vitamin K2
Application:
11/569,206 →
Publication:
US US20110064803A1
Nanoparticulate and Controlled Release Compositions Comprising a Cephalosporin
Application:
11/568,825 →
Publication:
US US20090269400A1
Nanoparticulate and Controlled Release Compositions Comprising a Platelet Aggregation Inhibitor
Application:
11/568,835 →
Publication:
US US20090297596A1
Nanoparticulate and Controlled Release Compositions Comprising Cefditoren
Nanoparticulate and Controlled Release Compositions Comprising Aryl-Heterocyclic Compounds
Application:
11/672,263 →
Publication:
US US20110008435A1
Nanoparticulate and controlled release compositions comprising nilvadipine
Application:
11/479,013 →
Publication:
US US20100247636A1
Nanoparticulate Formulations of Modafinil
Application:
11/776,770 →
Publication:
US US20080317843A1
Combination of a Narcotic and Non-Narcotic Analgesic
Application:
12/049,046 →
Publication:
US US20080226734A1
Compositions Comprising Nanoparticulate Naproxen and Controlled Release Hydrocodone
Application:
11/768,154 →
Publication:
US US20080113025A1
Compositions Comprising Nanoparticulate Meloxicam and Controlled Release Hydrocodone
Application:
11/768,169 →
Publication:
US US20080102121A1
Abuse-resistant pharmaceutical compositions
Drug Delivery Composition
Application:
12/757,005 →
Publication:
US US20100260858A1
Controlled-Release Clozapine Compositions
Application:
12/757,024 →
Publication:
US US20100260859A1
Dosing Regimen
Application:
12/209,728 →
Publication:
US US20090149479A1
Stable Liquid Formulations of Anti-Infective Agents and Adjusted Anti-Infective Agent Dosing Regimens
Application:
12/397,924 →
Publication:
US US20090227554A1
Reduction of Flake-Like Aggregation in Nanoparticulate Active Agent Compositions
Application:
12/788,196 →
Publication:
US US20100316725A1
Drug Delivery Device
Drug Delivery Device
Drug Delivery Device
Method of Inhibiting Neurotransmitter Activity Using Microencapsulated 3-PIPERIDINYL2-Substituted 1,2-Benzisoxazoles and 1,2-Benzisothiazoles
Application:
90/007,907 →
Microencapsulated 3_ Piperidinyl-Substituted 1,2-Benzisoxazoles and 1,2-Benzisothiszoles
Application:
90/008,151 →
Microencapsulated 3-Piperidinyl-Substituted 1,2 Benzisoxazoles and 1,2 Benzisothiazoles
Application:
90/008,212 →
Microencapsulated 3-Piperidinyl Substituted 1,2 Benzisoxazoles and 1,2 Benzisothiazoles
Application:
90/008,216 →
Preparation of a Biodegradable, Biocompatible Microparticles Containing a Biologically Active Agent
Application:
90/007,587 →
Preparation of Extended Shelf-Life Biodegradable, Biocompatible Microparticles Containing a Biologically Active Agent
Application:
90/008,093 →
Multiparticulate modified release composition
Application:
10/827,689 →
Publication:
US US20040197405A1
Method of Inhibiting Neuothransmitter Activity Using Microencapsulated 3-Piperidinyl-Substitituted 1,2-Benziosoxazoles and 1,2- Benzisothiazoles
Patent:
5,688,801 →
Application:
08/403,432 →
Microencapsulated 3-Piperidinyl-Substituted 1,2-Benzisoxazoles and 1,2-Benzisothiazoles
Patent:
5,965,168 →
Application:
09/005,549 →
Microencapsulated 3-Piperidinyl-Substituted 1,2-Benzisoxazoles and 1,2-Benzisothiazoles
Patent:
6,110,921 →
Application:
09/252,486 →
Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
Patent:
6,368,632 →
Application:
09/578,908 →
Microencapsulated 3-Piperidinyl-Substituted 1,2-Benzisoxazoles and 1,2-Benzisothiazoles
Microencapsulated 3-Piperidinyl-Substituted 1,2-Benzisoxazoles and 1,2-Benzisothiazoles
Microencapsulated 3-Piperidinyl-Substituted 1,2-Benzisoxazoles and 1,2-Benzisothiazoles
Microencapsulated 3-Piperidinyl-Substituted 1,2-Benzisoxazoles and 1,2-Benzisothiazoles
Preparation of Biodegradable Microparticles Containing a Biologically Active Agent
Patent:
5,650,173 →
Application:
08/725,439 →
Preparation of Biodegradable Microparticles Containing a Biologically Active Agent
Patent:
5,654,008 →
Application:
08/729,277 →
Preparation of Extended Shelf-Life Biodegradable, Biocompatible Microparticles Containing a Biologically Active Agent
Patent:
5,792,477 →
Application:
08/850,679 →
Preparation of Biodegradable, Biocompatible Microparticles Containing a Biologically Active Agent
Patent:
5,916,598 →
Application:
09/071,865 →
Preparation of Biodegradable, Biocompatible Microparticles Containing a Biologically Active Agent
Patent:
6,110,503 →
Application:
09/263,098 →
Preparation of biodegradable, biocompatible microparticles containing a biologically active agent
Patent:
6,290,983 →
Application:
09/578,717 →
Preparation of Biodegradable, Biocompatible Microparticles Containing a Biolgically Active Agent
Preparation of Microparticles Having a Selected Release Profile
Patent:
6,194,006 →
Application:
09/223,276 →
Preparation of microparticles having a selected release profile
Patent:
6,379,703 →
Application:
09/722,335 →
Preparation of Microparticles Having a Selected Release Profile
Preparation of Injectable Suspensions Having Improved Injectability
Patent:
6,495,164 →
Application:
09/577,875 →
Preparation of Injectable Suspensions Having Improved Injectability
Preparation of Injectable Suspensions Having Improved Injectability
Preparation of Injectable Suspensions Having Improved Injectability
Apparatus and Method for Preparing Microparticles
Patent:
6,331,317 →
Application:
09/438,659 →
Apparatus and Method for Preparing Microparticles
Apparatus and Method for Preparing Microparticles
Apparatus and Method for Preparing Microparticles
Apparatus and Method for Preparing Microparticles
Method for preparing microparticles having a selected polymer molecular weight
Patent:
6,264,987 →
Application:
09/575,075 →
Method for Preparing Microparticles Having a Selected Polymer Molecular Weight
Method for Preparing Microparticles Having a Selected Polymer Molecular Weight
Apparatus and Method for Preparing Microparticles Using Liquid-Liquid Extraction
Patent:
6,471,995 →
Application:
09/671,426 →
Apparatus for Preparing Microparticles Using Liquid-Liquid Extraction
Method for Preparing Microparticles Using Liquid-Liquid Extraction
Apparatus and Method for Preparing Microparticles Using in-Line Solvent Extraction
Patent:
6,495,166 →
Application:
09/438,656 →
Apparatus for Preparing Microparticles Using in-Line Solvent Extraction
Patent:
6,540,393 →
Application:
09/930,450 →
Method and Apparatus for Preparing Microparticles Using in-Line Solvent Extraction
Method and Apparatus for Preparing Microparticles Using in-Line Solvent Extraction
Method and Apparatus for Preparing Microparticles Using in-Line Solvent Extraction
Apparatus and Method for Preparing Microparticles Using in-Line Solvent Extraction
Acid end group poly(d,l-lactide-co-glycolide)copolymers High glycolide content
Patent:
6,362,308 →
Application:
09/635,677 →
Acid End Group Poly(D,L-Lactide-Co-Glycolide) Copolymers with High Glycolide Content
Acid End Group Poly(D,L-Lactide-Co-Glycolide) Copolymers with High Glycolide Content
Preparation of Microparticles Having Improved Flowability
Residual Solvent Extraction Method and Microparticles Produced Thereby
Residual Solvent Extraction Method and Microparticles Produced Thereby
Residual Solvent Extraction Method and Microparticles Produced Thereby
Residual Solvent Extraction Method and Microparticles Produced Thereby
Crosslinked Hydrogel Copolymers
Method and Apparatus for Filtering and Drying a Product
Microencapsulation and Sustained Release of Biologically Active Polypeptides
Microencapsulation and Sustained Release of Biologically Active Polypeptides
Polymer-Based Sustained Release Device
Polymer-Based Sustained Release Device
Polymer-Based Sustained Release Device
Polymorphic Forms of Naltrexone
Aripiprazole, Olanzapine and Haloperidol Pamoate Salts
Naltrexone Long Acting Formulations and Methods of Use
Composition for Sustained Release of Human Growth Hormone
Patent:
6,500,448 →
Application:
09/505,508 →
Composition and Method for the Controlled Release of Metal Cation-Stabilized Interferon
Patent:
5,711,968 →
Application:
08/279,784 →
Controlled Release of Metal Cation-Stabilized Interferon
Patent:
6,165,508 →
Application:
08/765,558 →
Controlled Release of Metal Cation-Stabilized Interferon
Production Scale Method of Forming Microparticles
Patent:
5,922,253 →
Application:
08/443,726 →
Production Scale Method of Forming Microparticless
Patent:
6,153,129 →
Application:
09/305,413 →
Production scale method of forming microparticles
Patent:
6,358,443 →
Application:
09/587,821 →
Production Scale Method of Forming Microparticles
Production Scale Method of Forming Microparticles
Method for Fabricating Polymer-Based Controlled-Release Devices
Patent:
5,817,343 →
Application:
08/649,128 →
Method for Fabricating Polymer-Based Controlled-Release Devices
Patent:
6,183,781 →
Application:
08/779,777 →
Composition and Method Using Solid-Phase Particles for Sustained in Vivo Release of a Biologically Active Agent
Patent:
5,916,597 →
Application:
08/705,197 →
Device for the Sustained Release of Aggregation-Stabilized, Biologically Active Agent
Patent:
6,514,533 →
Application:
08/934,830 →
Microencapsulation and Sustained Release of Oligonucleotides
Method for Purifying Human Growth Hormone
Patent:
6,451,347 →
Application:
09/260,362 →
Method of Producing Submicron Particles of a Labile Agent and Use Thereof
Patent:
6,444,223 →
Application:
09/321,091 →
Method of Producing Submicron Particles of a Labile Agent and Use Thereof
Method of Producing Sub-Micron Particles of Biologically Active Agents and Uses Thereof
Patent:
6,284,283 →
Application:
09/422,751 →
Method of Producing Sub-Micron Particles of Biologically Active Agents and Uses Thereof
Microencapsulation and Sustained Release of Biologically Active Acid-Stable or Free Sulfhydryl-Containing Proteins
Patent:
6,465,425 →
Application:
09/501,934 →
Process for the Preparation of Polymer-Based Sustained Release Compositions
Method and Apparatus for Uniform Sorbate Equilibration of Solid Samples
Patent:
6,499,361 →
Application:
09/507,238 →
Methods and Compositions for the Targeted Delivery of Biologically Active Agents
Method of Modifying the Release Profile of Sustained Release Compositions
Process for Producing Small Particles of Biologically Active Molecules
Patent:
6,569,458 →
Application:
08/006,682 →
Method of Preparing Sustained Release Microparticles
Increasing Blood-Brain Barrier Permeability with Permeabilizer Peptides
Patent:
5,506,206 →
Application:
08/121,058 →
Iodinated Aroyloxy Carboxamides
Patent:
5,260,478 →
Application:
07/986,646 →
Iodinated Aromatic Propanedioates
Patent:
5,264,610 →
Application:
08/038,371 →
Method of X-Ray Imaging Using Iodinated Aromatic Propanediates
Patent:
5,328,404 →
Application:
08/148,112 →
Use of Ionic Cloud Point Modifiers to Prevent Particle Aggregation During Sterilization
Patent:
5,298,262 →
Application:
07/987,904 →
Method to Reduce Particle Size Growth During Lyophilization
Patent:
5,302,401 →
Application:
07/987,879 →
X-Ray Contrast Compositions Useful in Medical Imaging
Patent:
5,451,393 →
Application:
08/207,533 →
Iodinated Aroyloxy Esters
Patent:
5,322,679 →
Application:
07/990,987 →
Polyiodinated Aroyloxy Esters
Patent:
5,466,433 →
Application:
08/261,794 →
Novel Formulations for Nanoparticulate X-Ray Blood Pool Contrast Agents Using High Molecular Weight Nonionic Surfactants
Patent:
5,326,552 →
Application:
07/991,909 →
Method of Making Nonoparticulate X-Ray Blood Pool Contrast Agents Using High Molecules Weight Nonionic Surfactants
Patent:
5,447,710 →
Application:
08/242,492 →
Iodinated Benzoyl Acetals and Ketals for X-Ray Imaging
Patent:
5,330,739 →
Application:
07/985,415 →
Use of Charged Phospholipids to Reduce Nanoparticle Aggregation
Patent:
5,470,583 →
Application:
08/240,309 →
Use of Non-Ionic Cloud Point Modifiers to Minimize Nanoparticle Aggregation During Sterilization
Patent:
5,346,702 →
Application:
07/985,424 →
Use of Purified Surface Modifiers to Prevent Particle Aggregation During Sterilization
Patent:
5,352,459 →
Application:
07/991,639 →
Iodinated Aromatic Compounds
Patent:
5,384,107 →
Application:
08/285,595 →
Surface Modified Anticancer Nanoparticles
Patent:
5,494,683 →
Application:
08/365,267 →
Water Insoluble Non-Magnetic Manganese Particles as Magnetic Resonance Contrast Enhancement Agents
Patent:
5,401,492 →
Application:
07/991,893 →
Use of Tyloxapol as a Nanoparticle Stabilizer and Dispersant
Patent:
5,429,824 →
Application:
07/990,874 →
Formulations of Oral Gastrointestinal Diagnostic X-Ray Contrast Agents in Combination with Pharmaceutically Acceptable Clays
Patent:
5,466,440 →
Application:
08/367,407 →
Nanoparticulate Diagnostic Mixed Carbonic Anhydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging
Patent:
5,643,552 →
Application:
08/524,145 →
Nanoparticulate Diagnostic Mixed Carbamic Anhydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging
Patent:
5,472,683 →
Application:
08/401,570 →
Nanoparticulate Diagnostic Mixed Carboxylic Anhydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging
Patent:
5,573,749 →
Application:
08/401,397 →
Iodinated Aroyloxy Ketones
Patent:
5,488,133 →
Application:
08/209,181 →
Nanoparticulate Diagnostic Dimers as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging
Patent:
5,500,204 →
Application:
08/386,788 →
Isolation of Ultra Small Particles
Patent:
5,503,723 →
Application:
08/385,531 →
Process of Preparing Therapeutic Compositions Containing Nanoparticles
Patent:
5,510,118 →
Application:
08/388,092 →
Method of Grinding Pharmaceutical Substances
Patent:
5,518,187 →
Application:
08/180,827 →
Nanoparticulate Nsaid Compositions
Patent:
5,518,738 →
Application:
08/385,614 →
Nanoparticulate Iodipamide Derivatives for Use as X-Ray Contrast Agents
Patent:
5,521,218 →
Application:
08/440,794 →
Nanoparticulate Diagnostic Diatrizoxy Ester X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging
Patent:
5,525,328 →
Application:
08/265,550 →
Method of Preparing Stable Drug Nanoparticles
Patent:
5,534,270 →
Application:
08/386,028 →
Process of Preparing X-Ray Contrast Compositions Containing Nanoparticles
Patent:
5,543,133 →
Application:
08/388,099 →
Formulations of Compounds as Nanoparticulate Dispersions in Digestible Oils or Fatty Acids
Patent:
5,571,536 →
Application:
08/384,057 →
Formulations of Compounds as Nanoparticulate Dispersions in Digestible Oils or Fatty Acids
Patent:
5,560,931 →
Application:
08/388,088 →
Microprecipitation of Nanoparticulate Pharmaceutical Agents
Patent:
5,560,932 →
Application:
08/370,955 →
Polyalkylene Block Copolymers as Surface Modifiers for Nanoparticles
Patent:
5,565,188 →
Application:
08/393,972 →
Pharmaceutical Compositions Containing Polyalkylene Block Copolymers Which Gel at Physiological Temperature
Patent:
5,705,194 →
Application:
08/727,863 →
Sulfated Nonionic Block Copolymer Surfactants as Stabilizer Coatings for Nanoparticle Compositions
Patent:
5,569,448 →
Application:
08/378,022 →
Diagnostic Imaging X-Ray Contrast Agents
Patent:
5,573,750 →
Application:
08/447,133 →
Redispersible Nanoparticulate Film Matrices with Protective Overcoats
Patent:
5,573,783 →
Application:
08/387,651 →
Site-Specific Adhesion Within the Gi Tract Using Nanoparticles Stabilized by High Molecular Weight, Linear Poly (Ethylene Oxide) Polymers
Patent:
5,580,579 →
Application:
08/388,878 →
Formulations of Oral Gastrointestinal Therapeutic Agents in Combination with Pharmaceutically Acceptable Clays
Patent:
5,585,108 →
Application:
08/366,518 →
Butylene Oxide-Ethylene Oxide Block Copolymer Surfactants as Stabilizer Coatings for Nanoparticle Compositions
Patent:
5,587,143 →
Application:
08/267,082 →
Milled Naproxen with Hydroxypropyl Cellulose as a Dispersion Stabilizer
Patent:
5,591,456 →
Application:
08/386,790 →
Novel Barium Salt Formulations Stabilized by Non-Ionic and Anionic Stabilizers
Patent:
5,593,657 →
Application:
08/386,027 →
3 5-Bis Alkanoyl Amino-2 4 6-Triiodobenzyl Esters
Patent:
5,603,916 →
Application:
08/447,132 →
Sugar Base Surfactant for Nanocrystals
Patent:
5,622,938 →
Application:
08/444,796 →
Formulations of Oral Gastrointestinal Diagnostic X-Ray Contrast Agents and Oral Gastrointestinal Therapeutic Agents
Patent:
5,628,981 →
Application:
08/366,841 →
Formulations for Therapeutic Agents Absorbed Through Mucous Membranes
Microprecipitation of Micro-Nanoparticulate Pharmaceutical Agents
Patent:
5,662,883 →
Application:
08/370,936 →
Co-Microprecipitation of Nanoparticulate Pharmaceutical Agents with Crystal Growth Modifiers
Patent:
5,665,331 →
Application:
08/370,998 →
Novel 3-Amido-Triiodophenyl Esters as X-Ray Contrast Agents
Patent:
5,668,196 →
Application:
08/677,709 →
2,4,6-Triiodo-5-Substituted-Amino-Isophthalate Esters Useful as X-Ray Contrast Agents for Medical Diagnostics
Patent:
5,670,136 →
Application:
08/586,363 →
Microprecipitation of Nanoparticulate Pharmaceutical Agents Using Surface Active Material Derived from Similar Pharmaceutical Agents
Patent:
5,716,642 →
Application:
08/370,928 →
Continuous Method of Grinding Pharmaceutical Substances
Patent:
5,718,388 →
Application:
08/249,787 →
Nanoparticles Containing the R(-)Enantiomer of Ibuprofen
Patent:
5,718,919 →
Application:
08/393,648 →
Aerosols Containing Beclomethazone Nanoparticle Dispersions
Patent:
5,747,001 →
Application:
08/393,973 →
Reduction of Intravenously Administered Nanoparticulate-Formulation- Induced Adverse Physiological Reactions
Patent:
5,834,025 →
Application:
08/696,754 →
Reduction of Intravenously Administered Nanoparticulate-Formulation-Induced Adverse Physiological Reactions
Patent:
41,884 →
Application:
12/027,100 →
Method of Grinding Pharmaceutical Substances
Patent:
5,862,999 →
Application:
08/491,539 →
Polyether Copolymers and a Process for Preparing Them
Patent:
5,936,030 →
Application:
08/836,819 →
Nanocrystalline Formulations of Human Immunodeficiency Virus (Hiv) Protease Inhibitors Using Cellulosic Surface Stabilizers
Patent:
6,045,829 →
Application:
08/890,602 →
Methods of Making Nanocrystalline Formulations of Human Immunodeficiency Virus (Hiv) Protease Inhibitors Using Cellulosic Surface Stabilizers
Patent:
6,068,858 →
Application:
09/225,493 →
Methods of Treating Mammals Using Nanocrystalline Formulations of Human Immunodeficiency Virus (Hiv) Protease Inhibitors
Patent:
6,221,400 →
Application:
09/225,498 →
Injectable Formulations of Nanoparticulate Naproxen
Patent:
6,153,225 →
Application:
09/154,422 →
New Solid Dose Form of Nanoparticulate Naproxen
Patent:
6,165,506 →
Application:
09/148,332 →
Nebulized Aerosals Containing Nanoparticulate Dispersions
Patent:
6,264,922 →
Application:
08/948,216 →
Dry Powder Aerosols of Nanoparticulate Drugs
Liquid Droplet Aerosols of Nanoparticulate Drugs
Patent:
6,811,767 →
Application:
09/597,738 →
Use of Peg-Derivatized Lipids as Surface Stabilizers for Nanoparticulate Compositions
Patent:
6,270,806 →
Application:
09/261,151 →
Methods for Preventing Crystal Growth and Particle Aggregation in Nanoparticulate Compositions
Patent:
6,267,989 →
Application:
09/263,834 →
Nanoparticulate Compositions Comprising Amorphous Cyclosporine and Methods of Making and Using Such Compositions
Patent:
6,656,504 →
Application:
09/392,557 →
Bioadhesive Nanoparticulate Compositions Having Cationic Surface Stabilizers
Bioadhesive Nanoparticulate Compositions Having Cationic Surface Stabilizers
Bioadhesive Nanoparticulate Compositions Having Cationic Surface Stabilizers
Small-Scale Mill and Method Thereof
Patent:
6,431,478 →
Application:
09/583,893 →
Small-Scale Mill and Method Thereof
Method of Using a Small Scale Mill
Rapidly disintegrating solid oral dosage form
Patent:
6,316,029 →
Application:
09/572,961 →
Solid Dose Nanoparticulate Compositions Comprising a Synergistic Combination of a Polymeric Surface Stabilizer and Dioctyl Sodium Sulfosuccinate
Patent:
6,375,986 →
Application:
09/666,539 →
Solid Dose Nanoparticulate Compositions Comprising a Synergistic Combination of a Polymeric Surface Stabilizer and Dioctyl Sodium Sulfosuccinate
Nanoparticulate Compositions Comprising Copolymers of Vinyl Pyrrolidone and Vinyl Acetate as Surface Stabilizers
Methods of Making Nanoparticulate Drug Compositions Comprising Copolymers of Vinyl Pyrrolidone and Vinyl Acetate as Surface Stabilizers
Apparatus for Sanitary Wet Milling
System and Method for Milling Materials
System and Method for Milling Materials
System and Method for Milling Materials
Nanoparticulate Compositions Having Lysozyme as a Surface Stabilizer
Gel Stabilized Nanoparticulate Active Agent Compositions
Nanoparticulate Megestrol Formulations
Nanoparticulate Fibrate Formulations
Methods of Treatment Using Nanoparticulate Fenofibrate Compositions
Nanoparticulate Polycosanol Formulations & Novel Polycosanol Combinations
In Vitro Methods for Evaluating the in Vivo Effectiveness of Dosage Forms of Microparticulate or Nanoparticulate Active Agent Compositions
In Vitro Methods for Evaluating the in Vivo Effectivness of Dosage Forms of Microparticulate or Nanoparticulate Active Agent Compositions
Nanoparticulate Topiramate Formulations
Sterilization of Dispersions of Nanoparticulate Active Agents with Gamma Radiation
Nanoparticulate Compositions Having a Peptide as a Surface Stabilizer
Injectable Nanoparticulate Olanzapine Formulations
Controlled Release Pharmaceutical Formulation
Patent:
5,505,962 →
Application:
08/307,392 →
Controlled Release Biodegradable Micro-and Nanospheres Containing Cyclosporin
Patent:
5,641,745 →
Application:
08/479,509 →
Controlled Absorption Diltiazem Formulation for Once Daily Administration
Patent:
5,364,620 →
Application:
07/921,459 →
Controlled Absorption Diltiazen Formulation for Once-Daily Administration
Patent:
5,616,345 →
Application:
08/334,864 →
Diltiazem Formulation and Methods of Treatment
Patent:
5,336,504 →
Application:
08/064,401 →
Formulations and Their Use in the Treatment of Neurological Diseases
Patent:
5,370,879 →
Application:
08/073,651 →
Formulations and Their Use in the Treatment of Neurological Diseases
Patent:
5,540,938 →
Application:
08/328,165 →
Formulations and Their Use in the Treatment of Neurological Diseases
Patent:
5,580,580 →
Application:
08/479,506 →
Passive Transdermal Device with Controlled Drug Delivery
Patent:
5,533,995 →
Application:
08/244,094 →
Oral Morphine Multiparticulate Formulation
Patent:
6,066,339 →
Application:
08/977,965 →
Multiparticulate modified release composition
Patent:
6,228,398 →
Application:
09/566,636 →
Multiparticulate Modified Release Composition
Multiparticulate Modified Release Composition
Multiparticulate Modified Release Composition
Multiparticulate Controlled Release Selective Serotonin Reuptake Inhibitor Formulations
Patent:
7,465,462 →
Application:
09/744,169 →
Apparatus and Method for Concurrently Monitoring Active Release and Physical Appearance of Solid Dosage Form Pharmaceuticals
Compositions Having a Combination of Immediate Release and Controlled Release Characteristics
Controlled Release Biodegradable Nanoparticles Containing Insulin
Patent:
5,641,515 →
Application:
08/474,161 →
Cap Assembly
Patent:
5,332,113 →
Application:
07/758,364 →
Liquid Delivery Device Particularly Useful for Delivering Drugs
Patent:
5,242,406 →
Application:
07/809,195 →
Transdermal Drug Delivery Device
Patent:
5,356,632 →
Application:
07/759,006 →
Transcutaneous Drug Delivery Applicator
Patent:
5,380,272 →
Application:
08/077,146 →
Device for Generating a Pulsatile Fluid Drug Flow
Patent:
6,312,409 →
Application:
09/331,648 →
Improved Electrode and Iontophoretic Devive and Method
Patent:
6,078,842 →
Application:
08/997,404 →
Device for the Delivery of a Substance to a Subject and Improved Electrode Assembly
Patent:
6,157,858 →
Application:
08/997,388 →
Drug Delivery Device
Patent:
6,317,630 →
Application:
09/239,934 →
Drug reconstitution and injection instrument
Patent:
454,194 →
Application:
29/135,976 →
Spike for Liquid Transfer Device, Liquid Transfer Device Including Spike, and Method of Transferring Liquids Using the Same
Intradermal Drug Delivery Device and Method for Intradermal Delivery of Drugs
Patent:
5,527,288 →
Application:
08/183,482 →
Intradermal Drug Delivery Device
Patent:
5,997,501 →
Application:
08/647,954 →
Mmedicament Delivery Device
Patent:
5,814,020 →
Application:
08/708,230 →
Cartridge-Based Drug Delivery Device
Patent:
5,858,001 →
Application:
08/763,311 →
Needle for Subcutaneous Delivery of Fluids
Patent:
6,261,272 →
Application:
09/202,176 →
Needle for subcutaneous delivery of fluids
Patent:
6,346,095 →
Application:
09/778,332 →
Drug Delivery Device
Patent:
6,530,900 →
Application:
09/577,033 →
Subcutaneous Drug Delivery Device with Improved Filling System
Patent:
6,186,982 →
Application:
09/072,875 →
Pre-Filled Drug-Delivery Device and Method of Manufacture and Assembly of Same
Patent:
6,500,150 →
Application:
09/103,716 →
Pre-Filled Drug-Delivery Device and Method of Manufacture and Assembly of Same
Pre-Filled Drug-Delivery Device and Method of Manufacture and Assembly of Same
Device and Method of Calibrating and Testing a Sensor for in Vivo Measurement of an Analyte
Patent:
6,275,717 →
Application:
09/102,840 →
Drug Delivery Kit and Method of Packaging the Same
Patent:
6,000,548 →
Application:
09/102,841 →
Adhesive System for Medical Devices
Drug Delivery Device
Patent:
6,595,956 →
Application:
09/275,464 →
Drug Delivery Device
Method and Device for Entrapping Gas Within a Liquid Drug Container
Patent:
6,520,941 →
Application:
09/415,961 →
Needle Device and Method Thereof
Electrolytic Cell
Methods and Compositions Using Liposome-Encapsulated Non-Steroidal Anti-Inflammatory Drugs
Patent:
6,759,057 →
Application:
07/323,182 →
Method for Size Separation of Particles
Patent:
5,948,441 →
Application:
08/367,923 →
Novel Emulsions
Patent:
5,626,873 →
Application:
08/442,080 →
Method for Entrapment of Cationic Species in Lemellar Vesicles
Patent:
5,525,232 →
Application:
08/137,371 →
Method of Separating Materials from Liposomes or Lipid Complexes
Patent:
5,716,526 →
Application:
08/599,869 →
Reduction of Liposome-Induced Adverse Physiological Reactions
Patent:
5,662,930 →
Application:
08/433,665 →
Reduction of Liposome-Induced Adverse Physiological Reactions
Patent:
5,614,214 →
Application:
08/247,053 →
Programmable Control Mounting System for Transdermal Drug Applicator
Patent:
5,591,123 →
Application:
08/381,141 →
Disposable Transdermal Drug Applicators
Patent:
5,358,483 →
Application:
07/949,721 →
Pulsating Transdernal Drug Delivery System
Patent:
5,372,579 →
Application:
08/204,784 →
Iodinated Wetting Agents
Patent:
5,346,688 →
Application:
07/991,640 →
Chemically Driven Liquid Delivery Pumping Device
Patent:
5,871,125 →
Application:
08/697,692 →
Related Assignments
(20)
Other recorded transfers of the patents in this record — the chain of ownership.
Merger
Oct 31, 2007
From: ALKERMES CONTROLLED THERAPEUTICS, II
To: ALKERMES, INC.
Reel/Frame 020035/0827 →
Assignment of Assignor's Interest
Mar 11, 2011
From: ALMARSSON, ORN; BLUMBERG, LAURA COOK; REMENAR, JULIUS F.
To: ALKERMES, INC.
Reel/Frame 025939/0379 →
Assignment of Assignor's Interest
Mar 11, 2011
From: BLUMBERG, LAURA COOK; ALMARSSON, ORN
To: ALKERMES, INC.
Reel/Frame 025941/0831 →
Patent Security Agreement (Second Lien)
Sep 29, 2011
From: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 026994/0245 →
Assignment of Assignor's Interest
Jun 27, 2012
From: ALKERMES, INC.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 028450/0795 →
Merger
Aug 2, 2012
From: ALKERMES CONTROLLED THERAPEUTICS, INC. II
To: ALKERMES, INC.
Reel/Frame 028712/0300 →
Assignment of Assignor's Interest
Aug 2, 2012
From: WRIGHT, STEVEN G.; CHRISTENSEN, TROY; YEOH, THEAN Y.; RICKEY, MICHAEL E.
To: ALKERMES CONTROLLED THERAPEUTICS, INC. II
Reel/Frame 028712/0257 →
Assignment of Assignor's Interest
Sep 12, 2012
From: ALKERMES, INC.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 028945/0855 →
Release of Security Interest
Oct 1, 2012
From: ELI LILLY AND COMPANY
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 029057/0342 →
Release by Secured Party (Second Lien)
Oct 12, 2012
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
Reel/Frame 029116/0379 →
Assignment of Assignor's Interest
Apr 19, 2013
From: ALKERMES, INC.
To: OTSUKA PHARMACEUTICAL CO., LTD.
Reel/Frame 030253/0038 →
Termination and Release of Security Interest in Patents (First Lien)
Feb 4, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 032161/0475 →
Assignment of Assignor's Interest
May 23, 2014
From: ALKERMES, INC.
To: OTSUKA PHARMACEUTICAL CO., LTD.
Reel/Frame 032959/0432 →
Assignment of Assignor's Interest
Oct 16, 2015
From: ALKERMES, INC.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 036809/0447 →
Release of Patent Security Agreement (First Lien)
Dec 24, 2024
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 069771/0548 →
Security Interest
Oct 23, 2025
From: ALKERMES, INC.
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 072656/0509 →
Security Interest
Oct 23, 2025
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 073213/0302 →
Security Interest
Feb 13, 2026
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 074858/0405 →
Release of Security Interest in Patents Previously Recorded at Reel/Frame (073213/0302)
Feb 13, 2026
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 074858/0429 →
Release of Security Interest in Patents Previously Recorded at Reel/Frame (072656/0509)
Feb 13, 2026
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ALKERMES, INC.
Reel/Frame 074858/0481 →